Merck licenses Abbisko’s pimicotinib in deal worth up to $605.5m
Under the agreement, Merck has the license to commercialise products comprising or containing CSF-1R inhibitor for all indications…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
05 Dec 23
Under the agreement, Merck has the license to commercialise products comprising or containing CSF-1R inhibitor for all indications…
05 Dec 23
The partnership combines AstraZeneca's expertise in oncology R&D with Absci's Integrated Drug Creation platform to expedite the discovery…
05 Dec 23
The proceeds from the funding round will be used by the company to advance the Phase 1 proof-of-mechanism…
04 Dec 23
Jaypirca (pirtobrutinib) 100mg or 50mg tablets taken as a once-daily 200 mg dose, is indicated for the treatment…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Dec 23
Under the partnership, the phenotypic drug discovery platform firm will have the global development, manufacturing, and commercialisation rights…
04 Dec 23
The production facility is a GMP pilot plant that will help GC Biopharma achieve its goal of internalising…
04 Dec 23
The topline data showed statistically significant change in body weight from baseline with danuglipron administration with changes at…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Dec 23
ARDENT is a Phase 1 study evaluating safety and tolerability of SC291 in patients with CLL and non-Hodgkin…
01 Dec 23
Through the acquisition of ImmunoGen for a total equity value of around $10.1bn, AbbVie is enabled to advance…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
01 Dec 23
In the study, etrasimod treatment produced a clinically meaningful and statistically significant improvement in primary endpoint as well…